Interleukin Genetics is pioneering a new commercialization model in personalized medicine in which it is being bankrolled by insurers who see the potential for lowering healthcare costs through utilization of molecular diagnostics.
This article has been updated from an earlier version with additional comments from Eliot Lurier.
By Turna Ray
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.